

MICRO-X COMPANY PRESENTATION

Adelaide, Australia, 29 July 2021: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for the healthcare and security markets globally, is pleased to provide the *attached Company Update* presentation, following the release of the June 2021 Quarterly Results and Activities Report.

The Company's management will also be conducting a series of meetings with investors and analysts following the Quarterly Investor Call on Thursday 29 July 2021.

This announcement is approved by Kingsley Hall, Company Secretary of Micro-X.

– ENDS –

About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: www.micro-x.com

CONTACTS

Micro-X Limited	Investor Enquiries
Peter Rowland Managing Director Tel: +61 8 7099 3966 E: prowland@micro-x.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com

MICRO-X

ACN 153 273 735
ASX: MX1

Company Update 29 July 2021

Peter Rowland
Managing Director & CEO



IMPORTANT NOTICE

DISCLAIMER

SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

MINIATURISING X-RAY

First Mover in Next Generation X-ray for Global Health and Security Markets

Platform technology in cold cathode x-ray

- X-ray products with significant reduction in size, weight and power
- **Patented technology** – platform for health and new security applications
- **First to market** with proven cold cathode medical x-ray product



29kg

Above: Conventional X-ray tube




1.5kg

Above: Micro-X tube

OUR STRATEGY

To Monetise Our 'First Mover' Advantage



OUR GOAL

Four production lines:

- **common technology platforms**
- **high-margin**
- **operating within five years**

OUR PRODUCTS



Mobile DR

Bedside Imaging – Medical, Military, Vet



IED X-ray Camera

Counter terrorist bomb assessment



Airport Checkpoint

Self-service airport security



Brain CT

In-ambulance stroke imaging

MOBILE DIGITAL RADIOLOGY

Extending Bedside Imaging with Light weight and Ultra-mobility

THE PRODUCT RANGE

OEM Products – Carestream DRX Revolution Nano

- First sold 2018 – now operating in 20+ countries
- Other, non-exclusive OEM partnerships in development

Micro-X ‘Rover’ – wholly Micro-X branded and controlled imaging solutions for:

- **Medical** hospitals & temporary facilities
- Ruggedized for deployed **military** hospitals and humanitarian aid
- **Veterinary** applications in small-animal hospitals



MOBILE DR – ROVER MEDICAL

Building Commercial Capability – New Markets and Sales Channels



Rover Medical – launched in mid 2021 with multiple distributors and dealerships



Focus now on building **installed base**



Building sales capability and channels globally



Varex detector – state of the art and higher margins



Two experienced sales managers hired – **US** and **EU**




Seattle Office opening – base for growing business opportunities in N America and supporting distributors



EMEA market entry - Roesys appointed distributor and Rover showcased at Arab Health 2021



Door-to-door x-ray services in Adelaide & Sydney proving success for point of care imaging at home



\$3.6m

Sales in FY21

4

New distributors signed

2021

Rover Mark II launch

MOBILE DR: ROVER FOR MILITARY & REMOTE USERS

First contract for ADF – Strong Military Interest for deployed medical facilities



Rover Military for use in **combat support**, disaster relief & humanitarian aid - addressing **unmet need**



Limited competition - means higher potential gross margins



FDA clearance - CE mark and TGA processes underway



Partnering - Rover Military uses the **Fuji detector**



\$1.3m contract for new **ADF** deployable hospital



Addressable market in **NATO countries** ~\$170M

\$1.4m

Sales via WHO in
Oct 2020

\$1.3m

Contract for ADF
Deployable Hospital

FDA

Cleared

MOBILE DR - ROVER VETERINARY

New Radiology Market – Same benefits for mobility



Rover Vet launched in **2021** for small animal veterinary market



Smaller size and mobility **improves workflows & productivity**



Veterinary user interface and imaging software – world leading



Australian launch **>3,000 vet practices** - all use radiology



First sale & specialist distributor appointed



Global veterinary roll-out to follow

3,000

Australian Vet Practices use diagnostic radiology

Unique

Workflow benefits

Sales

First sale June 2021

IED X-RAY CAMERA

Next Generation Security Device to Save Lives



Image of explosive actuator mechanism



First public showing of IED Camera at Army Robotics Conference in April 2021



X-Ray camera takes images like a camera - **one sided viewing** without separate detector



Bomb disposal technicians face life threatening situation when 'over the target' placing a conventional X-ray detector



Small size and weight - easily carried by robots



Australian Defence Force **proof of concept imaging completed**



Military and FBI / bomb disposal interest



No competition = high gross margins

\$1.8b

Addressable market

Prototype


By Dec 2021






2022

Target Launch

AIRPORT SELF-SERVICE CHECKPOINT

US Dept. of Homeland Security – Two Contracts Totalling US\$4m



-  A blend of backscatter and transmission X-ray to provide **three dimensional imaging of carry on luggage**
-  Integrated body scanner and passport reader
-  Based on work Micro-X is undertaking with the UK Government's Department for Transport
-  Concept reimagines the future of airport checkpoints based on self-service model
-  Addressable global market ~US\$24B
TSA alone US\$8B market opportunity

US\$24.0b

Addressable market

US\$4.0m

Two contracts for US
Dept of Homeland
Security

Above: Illustration of Future Airport Checkpoint Portal

BRAIN CT IMAGING FOR STROKE DIAGNOSIS

Pre-Hospital Diagnosis & Treatment in Ambulance - \$8m MRFF Funding Awarded



Illustration of curved ring scanner in ambulance setting



CT imaging with no moving parts – small enough and affordable to be fitted to every ambulance



Early stroke diagnosis allows treatment in a road or air ambulance – improved patient outcomes within the 'Golden Hour'




Curved detector will be the first of its kind - provided in collaboration with **Fujifilm**



\$8M funding under Second Phase of Australian Stroke Alliance Project – Medical Research Future Fund

Potential to be a game changer in modern stroke management with addressable market ~\$5bn



Above: Stroke Tomosynthesis Reconstruction and Display

US\$5.0b

Addressable market

\$8.0m

Australian Stroke Alliance - MRFF funding

Partners

MELBOURNE BRAIN CENTRE



FUJIFILM



SIGNIFICANT MARKETS ACROSS FOUR PRODUCTION LINES

Sequenced Product Rollout as CNT Manufacturing Expands



MOBILE DR RANGE

2018

First Sales

US\$500M pa*
Addressable Market




IED X-RAY CAMERA

2022*

First Sales

US\$1.8B
Addressable Market



AIRPORT CHECKPOINT

2023*

First Sales

USA: US\$8B
RoW: US\$16B
Addressable Market



BRAIN CT SCANNER

2026*

First Sales

US \$5B
Addressable Market

* Pre COVID-19 levels

* These dates are estimates and may vary

JUNE 2021 QUARTER HIGHLIGHTS

Advancing & Investing in our Commercial Capabilities



Congressman Adam Smith with the Micro-X team at the opening of the Seattle Office



Current (left) and future (right) Generators for the Rover range of Mobile DR x-ray products – future generator delivering four times more power

1

Expanding commercial range – New Mobile DR products

- Rover Medical receives FDA clearance – launched in US healthcare market
- Rover Veterinary launched – first sale and Australian distributor appointed
- Key components manufactured in house – control supply chain
- New detector allows control of sales channels – Direct + Dealers

2

New second generation tube & generator

- High voltage generator and X-ray tube tested – 4 times the x-ray energy at half the price
- Rover capabilities extended to trauma exams in emergency departments and operating theatres
- In-sourced manufacturing provides higher margins

3

Advancing our future technologies

- IED X-ray Camera – first public showcase to Australian Army Robotics conference
- Seattle premises opened – base for US sales and support for TSA programme management
- Early hires and pre-contract work underway for US Airport Security programmes (US\$4m) and Australian Stroke Alliance Brain CT Scanner programme (\$8m)

ESTABLISHED CAPABILITIES

Key Disciplines – Engineering Design, Development and Manufacturing



Above: manufacturing in Tonsley facility

EXPERIENCED LEADERSHIP

Technical and Commercial Expertise – To Support Objectives



Peter Rowland

Managing Director & CEO

- Over 30 years' engineering and management in medical device & aerospace industries
- Previously BAE Systems, Ellex Medical and Biolase Technology (NASDAQ)



David Knox

Non-Executive Chairman

- Extensive international business experience delivering large energy projects
- Formerly CEO of Santos and Australian Naval Infrastructure
- Chair of Snowy Hydro, Director of CSIRO



Patrick O'Brien

Non-Executive Director

- Over 25 years' business and finance experience in UK, Asia and Australia
- Former Executive Director at Macquarie Group; McKinsey; and Minter Ellison



Yasmin King

Non-Executive Director

- Extensive experience in business, negotiation & procurement and Government
- Currently CEO of Skills IQ, formerly Associate Commissioner of ACCC
- Director of the Australian Healthcare and Hospitals Association



Dr Alexander Gosling, AM

Non-Executive Director

- Over 40 years' business, technology and R&D experience
- A founding Director at Invetech (Vision Systems); strategy for Capstone



Jim McDowell


Non-Executive Director

- Extensive experience in Defence and Aerospace industries
- Current CEO of Nova Group
- Former Chief Executive of the Department of Premier for South Australia

CORPORATE SNAPSHOT

Growth Stage Company with Institutional Support

MX1 - Share Trading (27 July 2020 to 27 July 2021)



Share & Trading Statistics (Closing Price on 27 July 2021)	
Share Price	\$0.305 per share
Total Shares On Issue	459.7 million
Options Issued	2.5 million
Market Cap	~\$140.2m

Key Financials & Shareholders	
Cash	~\$30.1m (30 June 2021) – Debt free
Institutions	~40.0% Perennial (12.2%), Regal (10.9%), Thorney (6.3%), AusSuper (5.2%)
Board & Related Parties	~ 4.8%

MILESTONES & ACHIEVEMENTS

Initiatives to Deliver Commercial Outcomes for all Stakeholders

CY 2021

First IED X-ray Camera Demonstration

Growing Micro-X Rover paths to market – US, EMEA

In-sourced Generator tested

Launch Rover Veterinary

Rover Mk II – Second generation Launch

Airport Security Contracts Signed

Brain CT Scanner Contract signed

IED X-ray Camera prototype

BEYOND

Increasing Mobile DR Sales

Scaling x-ray tube manufacturing

IED X-ray Camera Commercialisation

Brain CT Scanner Prototype

Airport Security Scanner Prototype

Airport Security Portal Prototype

MICRO-X

ACN 153 273 735
ASX: MX1

Thank You

Peter Rowland
Managing Director & CEO

